Bempikibart (ADX-914) is under development for the treatment of atopic dermatitis and alopecia areata. It is administered through subcutaneous route and acts by targeting interleukin-7 receptor (IL-7R ...
Shares of Q32 Bio Inc. (NASDAQ:QTTB – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eight ...
Hosted on MSN24d
Here's Why Q32 Bio Stock Hit a New Record Low on WednesdayQTTB Stock Performance Following the news, shares of Q32 Bio hit an all-time low of $5.80. The latest announcement did not impress investors, who raised concerns about the drug’s efficacy. Wall ...
Q32 Bio Inc. (NASDAQ:QTTB – Get Free Report) was the target of a large growth in short interest in the month of December. As ...
Piper Sandler analyst Christopher Raymond lowered the firm’s price target on Q32 Bio (QTTB) to $20 from $85 and keeps an Overweight rating on ...
Dec. 10, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today ...
Oppenheimer lowered the firm’s price target on Q32 Bio (QTTB) to $20 from $80 and keeps an Outperform rating on the shares. The firm notes Q32 Bio reported negative AD but positive AA results ...
Wells Fargo analyst Derek Archila downgraded Q32 Bio (QTTB) to Equal Weight from Overweight with a price target of $16, down from $95. The firm is “disappointed” bempikibart’s Phase 2 study ...
"On behalf of Q32 Bio, I want to express my gratitude to the patients, their caregivers, and clinical trial sites that participated across both our bempikibart Phase 2a trials." The Company is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback